<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147965">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01862887</url>
  </required_header>
  <id_info>
    <org_study_id>A6631035</org_study_id>
    <nct_id>NCT01862887</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of PH-797804 on QTc Interval</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-And Positive-Controlled Crossover Study To Determine The Effect Of A Single-Dose Of PH-797804 On QTc Interval In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of PH-797804 following dosing of a 24
      mg oral tablet on the QTc interval
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>QTcF Interval</measure>
    <time_frame>-1.5,-1,-0.5,0.5,2,4,5,6,7,8,12,24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QT interval corrected for heart rate using Fredericias correction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcI Interval</measure>
    <time_frame>-1.5,-1,-0.5,0.5,2,4,5,6,7,8,12,24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QT interval using individual heart rate correction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]</measure>
    <time_frame>0,0.5,2,4,5,6,7,8,12,24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0,0.5,2,4,5,6,7,8,12,24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0,0.5,2,4,5,6,7,8,12,24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PH-797804</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 24 mg dose in the fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 400 mg dose in the fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single placebo dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH-797804</intervention_name>
    <description>Tablet, 24 mg, single dose</description>
    <arm_group_label>PH-797804</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Tablet, 400 mg, single dose</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, PH-797804 matched placebo, single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects and/or healthy female subjects of non-child bearing potential
             between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically
             relevant abnormalities identified by a detailed medical history, full physical
             examination, including blood pressure and pulse rate measurements, 12-lead ECG and
             clinical laboratory tests.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt; 50 kg (110
             lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  A positive urine drug screen.

          -  History of regular alcohol consumption exceeding 14 drinks/week for males.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6631035&amp;StudyName=A%20Study%20to%20Investigate%20the%20Effect%20of%20PH-797804%20on%20QTc%20Interval</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 14, 2013</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
